Resistance training combined with blood flow restriction in cirrhosis: study protocol for a randomized controlled trial

• Main Authors: Sanmy Rocha Nóbrega, Silvana Gama Florencio Chachá, Cleiton Augusto Libardi
• Format: Article
• Language: English
• Published: BMC 2020-05-01
• Series: Trials
• Subjects: End stage liver disease; Sarcopenia; Physical activity; Muscle strength; Quality of life; Hypertrophy
• Online Access: http://link.springer.com/article/10.1186/s13063-020-04410-2

Abstract Background Patients affected by hepatic cirrhosis show reductions in muscle mass and function, with poor quality of life and functional performance. As such, resistance training with blood flow restriction (BFR-RT) could be a useful therapeutic tool for health promotion. Thus, we aim to verify the effects of this intervention on muscle strength, muscle mass, fiber Pennation angle, fascicle length, functional performance, quality of life, and fall risk scores in this population. Methods Thirty participants will be randomly distributed between 1) BFR-RT and 2) control (CTRL). Assessments will occur at three time points: before the training intervention (0 W), after 12 weeks (12 W), and at follow-up (24 W). The following variables will be assessed: Child-Pugh classification; MELD score; SF-36 questionnaire; fatigue severity index; 6-min walk test; timed-up and go; 30-s sitting and rising test; dietary record; one-repetition maximum (1-RM) strength test (knee extension exercise); and vastus lateralis’ cross-sectional area, Pennation angle, and fascicle length. The BFR-RT group will undergo 12 weeks of knee extension exercise (1 × 30 repetitions and 3 × 15 repetitions at 20% 1-RM and 50% of total blood flow occlusion pressure), with two sessions per week. Data normality will be assessed using the Shapiro-Wilk test. In case of normal distribution, a one-way repeated measures analysis of variance will be implemented to test for differences in baseline values. A mixed model then will be applied for each dependent variable. In case of non-normal data distribution, a Kruskal–Wallis test will be implemented to test for differences in baseline values. Next, the Friedman test will be used to analyze repeated measures. Within- and between-group effect sizes will be calculated using Cohen’s d for each outcome. Finally, the minimal clinically important difference will be analyzed with distribution-based methods. Discussion To our knowledge, this will be the first trial to investigate BFR-RT in patients with cirrhosis and evaluate the effects on neuromuscular parameters, functional performance, disease severity, and quality of life outcomes. Trial registration Brazilian Clinical Trials Registry (ReBec): RBR-395mfw . Registered on 25 August 2018.